West Pharmaceutical Services, Inc. (WST)
NYSE: WST · Real-Time Price · USD
353.08
-0.69 (-0.20%)
Aug 21, 2026, 4:00 PM EDT - Market closed
WST Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,327 | 3,074 | 2,893 | 2,950 | 2,887 | 2,832 | |
Revenue Growth | 12.38% | 6.25% | -1.92% | 2.18% | 1.95% | 31.89% |
Cost of Revenue | 2,103 | 1,970 | 1,895 | 1,820 | 1,751 | 1,654 |
Gross Profit | 1,224 | 1,104 | 998.5 | 1,130 | 1,136 | 1,178 |
Selling, General & Admin | 418.6 | 389.7 | 334.9 | 354.1 | 316 | 356.3 |
Research & Development | 74.4 | 74.3 | 69.1 | 68.4 | 58.5 | 52.8 |
Other Operating Expenses | - | 1.3 | 0.9 | 1.3 | -2.1 | - |
Operating Expenses | 493 | 465.3 | 404.9 | 423.8 | 372.4 | 409.1 |
Operating Income | 730.8 | 638.7 | 593.6 | 706.2 | 763.8 | 768.6 |
Interest Expense | -4.5 | -0.5 | -3 | -9 | -7.9 | -8.2 |
Interest & Investment Income | 18.7 | 17.5 | 19.6 | 28 | 5.1 | 1 |
Earnings From Equity Investments | 15.5 | 14.4 | 14.7 | 17.7 | 20.7 | 20.1 |
Currency Exchange Gain (Loss) | -8.5 | -8.4 | -10.2 | -9.4 | 4.1 | 1.4 |
EBT Excluding Unusual Items | 752 | 661.7 | 614.7 | 733.5 | 785.8 | 782.9 |
Merger & Restructuring Charges | -21.3 | -29.5 | -2.1 | 2 | -23.8 | -2.2 |
Gain (Loss) on Sale of Investments | -8 | -4.5 | -0.3 | -4.3 | -3.5 | -4.3 |
Gain (Loss) on Sale of Assets | - | - | - | -11.6 | - | - |
Asset Writedown | -3.3 | -3.7 | -7 | -5.3 | -2.7 | -4.1 |
Legal Settlements | - | - | - | 3.8 | - | - |
Other Unusual Items | -10.3 | -8.7 | -5.1 | -2.4 | -55.2 | -3.3 |
Pretax Income | 709.1 | 615.3 | 600.2 | 715.7 | 700.6 | 769 |
Income Tax Expense | 144.2 | 121.6 | 107.5 | 122.3 | 114.7 | 107.2 |
Net Income | 564.9 | 493.7 | 492.7 | 593.4 | 585.9 | 661.8 |
Net Income to Common | 564.9 | 493.7 | 492.7 | 593.4 | 585.9 | 661.8 |
Net Income Growth | 15.83% | 0.20% | -16.97% | 1.28% | -11.47% | 91.16% |
Shares Outstanding (Basic) | 72 | 72 | 73 | 74 | 74 | 74 |
Shares Outstanding (Diluted) | 72 | 73 | 74 | 75 | 76 | 76 |
Shares Change | -1.16% | -1.36% | -2.13% | -0.66% | -0.66% | 0.66% |
EPS (Basic) | 7.86 | 6.83 | 6.75 | 7.99 | 7.88 | 8.90 |
EPS (Diluted) | 7.81 | 6.79 | 6.69 | 7.88 | 7.73 | 8.67 |
EPS Growth | 16.82% | 1.49% | -15.10% | 1.94% | -10.84% | 89.72% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 436.9 | 468.9 | 276.4 | 414.5 | 439.4 | 330.6 |
Free Cash Flow Per Share | 6.05 | 6.45 | 3.75 | 5.50 | 5.80 | 4.33 |
Dividend Per Share | 0.870 | 0.850 | 0.810 | 0.770 | 0.730 | 0.690 |
Dividend Growth | 4.82% | 4.94% | 5.20% | 5.48% | 5.80% | 6.15% |
Gross Margin | 36.79% | 35.91% | 34.51% | 38.31% | 39.36% | 41.59% |
Operating Margin | 21.97% | 20.78% | 20.52% | 23.94% | 26.46% | 27.14% |
Profit Margin | 16.98% | 16.06% | 17.03% | 20.12% | 20.29% | 23.37% |
Free Cash Flow Margin | 13.13% | 15.25% | 9.55% | 14.05% | 15.22% | 11.68% |
EBITDA | 912.2 | 810.1 | 749 | 843.5 | 884.4 | 890.9 |
EBITDA Margin | 27.42% | 26.35% | 25.89% | 28.59% | 30.64% | 31.46% |
D&A For EBITDA | 181.4 | 171.4 | 155.4 | 137.3 | 120.6 | 122.3 |
EBIT | 730.8 | 638.7 | 593.6 | 706.2 | 763.8 | 768.6 |
EBIT Margin | 21.97% | 20.78% | 20.52% | 23.94% | 26.46% | 27.14% |
Effective Tax Rate | 20.34% | 19.76% | 17.91% | 17.09% | 16.37% | 13.94% |